National Bloood Authority Annual Report 2010–11
Total Page:16
File Type:pdf, Size:1020Kb
NATIONAL BLOOD AUTHORITY BLOOD NATIONAL NATIONAL BLOOD AUTHORITY AUSTRALIA ANNUAL REPORT 2010–2011 AUSTRALIA ANNUAL REPORT ANNUAL 2010–2011 NATIONAL BLOOD AUTHORITY AUSTRALIA ANNUAL REPORT 2010–2011 Our mission is to secure a quality blood supply through world leading contractual arrangements; promote safe, high quality management and use of blood and blood products in Australia; and drive continual performance improvement across the sector. NBA 38977 Annual Report 2010-11_Text_AW4.indd i 14/10/11 5:23 PM ii 2010–11 With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under a Creative Commons Attribution 3.0 Australia (http://creativecommons.org/licenses/by/3.0/au/) licence. ANNUAL REPORT The details of the relevant licence conditions are available on the Creative Commons NBA website (accessible using the links provided) as is the full legal code for the CC BY 3.0 AU licence (http://creativecommons.org/licenses/by/3.0/au/legalcode). The content obtained from this document or derivative of this work must be attributed as the National Blood Authority annual report 2010–11. ISSN 1832–1909 This report is available online at: www.nba.gov.au/pubs/annual-report.html Printed by: Paragon Printers Australasia Designed by: Swell Design Group Contact offi cer: Stephanie Gunn Acting CEO and General Manager Locked Bag 8430 Canberra ACT 2601 Telephone: 02 6211 8300 Facsimile: 02 6211 8330 Email: [email protected] Website: www.nba.gov.au Images of blood and blood products contained in graphics are courtesy of NBA’s suppliers. NBA 38977 Annual Report 2010-11_Text_AW4.indd ii 14/10/11 5:23 PM LETTER OF TRANSMITTAL iii The Hon Nicola Roxon MP Minister for Health and Ageing Parliament House Canberra ACT 2600 LETTER OF TRANSMITTAL Dear Minister, I am pleased to present the 2010–11 annual report of the National Blood Authority (NBA) and the National Blood Authority Board. This document has been prepared in accordance with sub-sections 44(1) and 44(2) of the National Blood Authority Act 2003, sub-sections 63(2) and 70(2) of the Public Service Act 1999, section 5 of the Financial Management and Accountability Act 1997 and the July 2011 Annual Report Requirements published by the Department of the Prime Minister and Cabinet. I certify that all of the requirements have been addressed. I certify that the National Blood Authority has prepared fraud risk assessments and fraud control plans and has in place appropriate fraud prevention, detection, investigation, reporting and data collection procedures and processes that meet the specifi c needs of the agency and has complied with the requirements of the Commonwealth Fraud Control Guidelines. Yours sincerely, Stephanie Gunn Acting General Manager and Chief Executive Offi cer National Blood Authority 7 October 2011 NBA 38977 Annual Report 2010-11_Text_AW4.indd iii 14/10/11 5:23 PM iv CONTENTS Letter of transmittal iii User Guide viii 2010–11 Part 1: Overview 1 1.1 NBA role and responsibilities 2 1.2 Blood products and how they are used 3 1.3 The Australian blood supply chain 6 ANNUAL REPORT 1.4 Blood sector governance 8 NBA 1.5 Blood sector funding 9 Part 2: Highlights of 2010–2011 10 2.1 Snapshot of the blood sector in 2010–11 12 2.2 General Manager’s review 14 2.3 NBA Board report 16 2.4 Principal Medical Offi cer’s review 20 Part 3: Performance 22 3.1 Performance framework 24 3.2 Supply of blood and blood products 25 Highlights: Output based funding—improving accountability 41 State-of-the-art processing centre opens 45 Securing supply—improving value for money 52 3.3 Management of risk and sector performance improvement 56 Highlights: Voluntary recall—NBA ensures IVIg supply 59 BloodNet: value adding in the supply chain 61 3.4 Appropriate patient blood management 70 and safe use of blood and blood products Highlight: New advice to guide clinical practice 72 Part 4: Horizon scanning 82 4.1 Introduction 84 4.2 Fresh blood 86 4.3 Blood management 97 4.4 Plasma and recombinant products 100 NBA 38977 Annual Report 2010-11_Text_AW4.indd iv 14/10/11 5:23 PM v Part 5: Corporate governance 110 5.1 Governance structure 112 5.2 Planning and service delivery 116 CONTENTS 5.3 People management 118 Part 6: Financial management and accountability 124 6.1 Budget and fi nancial management 126 6.2 Purchasing 131 6.3 Asset management 135 6.4 Financial statements 136 Appendices 186 A1 The National Blood Agreement: objectives of governments 188 A2 Blood sector stakeholders and governance 189 A3 National Blood Authority agency resource statement 192 A4 Biographies of NBA Board members 194 A5 Fresh blood components supplied under contract by the Blood Service in 2010–11 199 A6 Plasma and recombinant products supplied under contract in 2010–11 200 A7 Units of red cells, platelets and IVIg issued per 1000 head of population 203 by state and territory 2007–08 to 2010–11 A8 Biographies of NBA senior managers 205 A9 Responsibilities and composition of NBA governance committees 208 A10 Mandatory reporting: 210 Disability reporting 210 Occupational health and safety 210 Ecologically sustainable development and environmental reporting 211 Freedom of Information 215 A11 Errata 217 A12 Glossary of terms and acronyms 218 A13 List of requirements 227 Index 232 NBA 38977 Annual Report 2010-11_Text_AW4.indd v 14/10/11 5:23 PM vi Tables 1.1 Government funding to the NBA for the supply of blood and blood products, 2010–11 2003–04 to 2010–11 1.2 Government funding for the operation of the NBA, 2003–04 to 2010–11 3.1 Blood and blood products purchased, by suppliers, 2008–09 to 2010–11 3.2 Variance between actual supply of fresh blood components against the annual supply estimates ANNUAL REPORT 3.3 Blood Service: annual funding 2003–04 to 2010–11 NBA 3.4 Blood Service: selected key performance indicators, 2010–11 3.5 Blood Service plasma volumes collected, 2003–04 to 2010–11 3.6 Red cell age at issue by quarter, 2009–10 to 2010–11 3.7 Blood Service annual capital plan expenditure, 2006–07 to 2010–11 3.8 Blood Service Change Program projects and funding, 2010–11 3.9 CSL Limited: annual funding for plasma fractionation, 2003–04 to 2010–11 3.10 CSL Australian Fractionation Agreement: key performance indicators, 2010–11 3.11 Octapharma Australia: key performance indicators, 2010–11 3.12 Annual expenditure on imported products (excluding intravenous immunoglobulin), by company, 2003–04 to 2010–11 3.13 Imported recombinant blood product contracts: key performance indicators, by supplier, 2010–11 3.14 Changes in suppliers of imported plasma and recombinant blood products 3.15 Comparison of the proportion of patients in registers and treated, UK and Australia, major diagnoses 2010 3.16 Focus of the red cell data linkage project 5.1 NBA performance in achieving objectives of its operational plans, 2006–07 to 2010–11 5.2 Number of NBA staff at 30 June 2011 5.3 Numbers of NBA staff on types of employment agreements 5.4 Salary levels of NBA staff at 30 June 2011 6.1 Overall funding and expenditure for the NBA in 2010–11: a summary 6.2 Key results in fi nancial performance, 2010–11, 2009–10 and 2008–09 6.3 Administered revenue, 2010–11, 2009–10 and 2008–09 6.4 Key results of administered expenses, 2010–11, 2009–10 and 2008–09 6.5 Expenditure on consultancy services, 2007–08 to 2010–11 6.6 Consultancy services of $10,000 or more, 2010–11 NBA 38977 Annual Report 2010-11_Text_AW4.indd vi 14/10/11 5:23 PM vii Figures 1.1 The blood product family 1.2 The Australian blood and blood products supply chain CONTENTS 1.3 Governance structure of the Australian blood sector 3.1 NBA’s outcome, program and activity structure 3.2 Funding by product category 2010–11 3.3 Actual issues performance against the NSP&B and the mid-year review, 2007–08 to 2010–11 3.4 Fresh blood expenditure: increases on 2003–04 base year 3.5 Red cells issued by the Blood Service, 2007–08 to 2010–11 3.6 Red cells issued per 1000 head of population, 2007–08 to 2010–11 3.7 Platelets issued by the Blood Service, 2007–08 to 2010–11 3.8 Platelets issued per 1000 head of population, 2007–08 to 2010–11 3.9 Plasma-derived and overseas product expenditure: cumulative increases on 2003–04 base year 3.10 Issues of Factor VIII products, 2007–08 to 2010–11 3.11 Issues of total Factor VIII per 1000 head of population, 2007–08 to 2010–11 3.12 Market share of recombinant Factor VIII issues, 2007–08 to 2010–11 3.13 Issues of Factor IX products, 2007–08 to 2010–11 3.14 Issues of Factor IX products per 1000 head of population, 2007–08 to 2010–11 3.15 Issues of recombinant Factor VIIa, 2007–08 to 2010–11 3.16 Issues of FEIBA, 2007–08 to 2010–11 3.17 Issues of IVIg products, 2007–08 to 2010–11 3.18 Issues of IVIg (grams) per 1000 head of population, 2007–08 to 2010–11 3.19 Top ten uses of IVIg, 2004–05 to 2010–11 3.20 Framework for the new Deed of Agreement with the ARCS for the Blood Service 3.21 Days of inventory at the Blood Service, of major blood type, by month, 2009–10 to 2010–11 3.22 Market share for suppliers of diagnostic reagent products, 2007–08 to 2010–11 3.23 TRALI: chest x-ray fi ndings 3.24 Red cell data linkage datasets 4.1 Scope of the NBA’s horizon scanning 5.1 NBA’s organisational structure as at 30 June 2011 NBA 38977 Annual Report 2010-11_Text_AW4.indd vii 14/10/11 5:23 PM viii USER GUIDE This is the annual report of the NBA for the 2010–11 fi nancial year.